Literature DB >> 11266425

The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens.

M Cizman1, M Pokorn, K Seme, A Orazem, M Paragi.   

Abstract

The correlation between increased macrolide consumption and the resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to macrolides in Slovenia from 1994 to 1999 was evaluated. The outpatient consumption of macrolides increased from 1.89 to 3.84 defined daily doses (DDD)/1000 inhabitants/day during the observation period. This increase in macrolide consumption was paralleled by a steady increase in macrolide resistance in S. pyogenes (from 0 to 7.4%, r = 0.90, P = 0.014) and upper respiratory S. pneumoniae isolates (from 0 to 9%, r = 0.82, P = 0.044). In other pathogens studied, no significant increase was detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266425     DOI: 10.1093/jac/47.4.475

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  The geographic relationship between the use of antimicrobial drugs and the pattern of resistance for Streptococcus pneumoniae in Italy.

Authors:  D Boccia; S Spila Alegiani; A Pantosti; M L Moro; G Traversa
Journal:  Eur J Clin Pharmacol       Date:  2004-03-10       Impact factor: 2.953

2.  In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.

Authors:  Takafumi Sato; Kazuhiro Tateda; Soichiro Kimura; Morihiro Iwata; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

3.  M.SpyI, a DNA methyltransferase encoded on a mefA chimeric element, modifies the genome of Streptococcus pyogenes.

Authors:  Chad W Euler; Patricia A Ryan; Judith M Martin; Vincent A Fischetti
Journal:  J Bacteriol       Date:  2006-11-03       Impact factor: 3.490

Review 4.  Antibacterial resistance.

Authors:  Jocelyn Y Ang; Elias Ezike; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

Review 5.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

6.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

7.  Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Pauliina Kärpänoja; Solja T Nyberg; Miika Bergman; Tinna Voipio; Pirkko Paakkari; Pentti Huovinen; Hannu Sarkkinen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

8.  Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers.

Authors:  M Eisenblätter; C Klaus; M W R Pletz; H Orawa; H Hahn; J Wagner; H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-30       Impact factor: 3.267

9.  Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania.

Authors:  Michael Green; Judith M Martin; Karen A Barbadora; Bernard Beall; Ellen R Wald
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance.

Authors:  Stefania Cresti; Maria Lattanzi; Alessandra Zanchi; Francesca Montagnani; Simona Pollini; Carla Cellesi; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.